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Background: Little is known about characteristics of patients receiving allergen-specific immunotherapy.
Identifying obstacles to appropriate treatment according to guidelines may facilitate the development
of strategies aiming at improved treatment of patients with allergic respiratory diseases. The objective
of this study was to investigate differences in disease severity, demographic and socioeconomic status
between allergic rhinitis patients receiving allergen-specific immunotherapy and allergic rhinitis
patients not receiving allergen-specific immunotherapy. Methods: A total of 366 patients were
studied of whom 210 were going to receive subcutaneously administrated immunotherapy (SIT)
against grass pollen and/or house dust mite allergy. The severity of rhino-conjunctivitis (hay fever)
and/or asthma was classified according to international guidelines. The questionnaires included an
EQ-5D visual analogue scale instrument and some socio-economic questions. Results: Severity of
disease, young age, high level of education as well as greater perceived impairment of health-related
quality of life due to allergic symptoms were significantly associated with use of SIT. Somewhat unex-
pectedly, household income was not associated with use of SIT. Conclusion: Use of SIT was associated
with both disease severity measures and educational level, but not income level. These results suggest
social inequality as reflected by lower use of SIT among patients with lower educational level may
represent an obstacle to treatment with SIT.
Keywords: asthma, hay fever, health services needs and demand, immunological desensitization,
quality of life
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Introduction
In Europe, 25% of the population suffers from respiratoryallergy. Thus, allergies constitute a major public health
problem, and is associated with impairment of health-related
quality of life (HRQL).1–3 Allergen-specific treatment targets
the specific allergic immune response that triggers symptoms
and the underlying inflammatory condition of the airways.
There are two main options for allergen-specific treatment:
allergen avoidance and allergy-specific immunotherapy.
While the efficacy of allergen avoidance is debated, there is
strong evidence that immunotherapy using inhalant allergens
are clinically effective in the treatment of allergic respiratory
diseases (ARD).4 Allergen-specific subcutaneous injection im-
munotherapy (SIT) with Alutard SQ induces clinical and im-
munological tolerance, has long-term efficacy, and may
prevent the progression of allergic disease. This treatment
also improves the HRQL of allergic patients.5,6 The clinical
efficacy of SIT is well established for both allergic rhinitis
and allergic asthma.7–9 There is evidence that under-diagnosis
and under-treatment of allergic rhinitis patients are
substantial1,10–12 despite internationally approved guidelines
and available effective treatments. In Denmark, few persons
with grass pollen allergic rhinitis in the general population
have ever received grass pollen SIT.13 Data from the Danish
Medicines Agency show that <0.1% of people allergic to grass
pollen and/or house dust mites were treated with SIT in
Denmark in the year 2007. In addition, there were great
variations in the vaccination rates and turnover between the
five administrative regions in Denmark.14 The primary health
care sector in Denmark includes general practitioners (GPs)
and specialist doctors. The observed variation is likely to be
explained by variations in need, supply and demand.
Differences in need will arise to the extent that there are dif-
ferences in the prevalence and severity of allergy between urban
and rural areas, for example.15 Lack of specialist doctors and
GPs in some areas may be an obstacle to health care and could
explain low vaccination rates in these areas. This notion is
supported by the fact that the number of practising specialists
per 10 000 inhabitants in Danish counties varies from 0.8 in
the county of Ringkøbing to 3.6 in the county of the Capital.
European Journal of Public Health, Vol. 21, No. 3, 323–328
 2010. The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://
creativecommons.org/licenses/by-nc/2.0), which permits unrestricted non-commercial use, distribution, and reproduction in any
medium, provided the original work is properly cited.
doi:10.1093/eurpub/ckq063 Advance Access published on 19 May 2010
 by guest on January 15, 2017
http://eurpub.oxfordjournals.org/
D
ow
nloaded from
 
Subcutaneously administered SIT is a time-consuming
treatment involving weekly injections during the up-dosing
phase followed by maintenance doses given at 6 2 weeks
intervals for 3–5 years depending on vaccine properties and
disease factors. Little is known about characteristics of patients
receiving SIT. Identifying obstacles to appropriate treatment
according to guidelines may facilitate the development of
strategies for the public health policy and practice aiming at
improved treatment of patients with ARD.
According to the human capital theory,16,17 individuals
invest in their own health through education, physical
exercise and health care in order to feel better and increase
future earnings. Thus, the demand for health care is complex,
since health care can be regarded as a consumption good as
well as an investment good.18 Willingness to invest in health
care in order to gain positive health outcomes in the longer
run is a function of individuals’ time preference, and thus the
rate at which they discount future outcomes. Since SIT is a
treatment programme which requires significant resource in-
vestments (in terms of time, effort and out-of-pocket
payments) at present with the prospect of future gains, indi-
viduals who operate with high discount rates are less likely to
demand SIT. Results have shown that there is a correlation
between education and time preferences.19 Thus, we would
expect that individuals with higher levels of education would
be more prone to demand SIT. Other relevant demand side
factors could be age, gender and income. Younger age is
associated with a higher expected outcome of SIT due to a
longer life expectancy. Younger individuals may also perceive
allergy and asthma to impact more significantly on the HRQL,
due to higher expectations and a more active life. Hence, we
expect that younger individuals will be more likely to demand
SIT. The out-of-pocket payment for SIT is 4500 DK (E600)
over a period of 3 years, and may thus represent a barrier for
consuming SIT, especially for those with a lower income, since
for these people such an out-of-pocket expense would
constitute a higher opportunity cost. Consequently, we hy-
pothesize that individuals with lower income will be
underrepresented amongst those individuals who demand
SIT. Furthermore, we expect that patients with the greatest
objective need for SIT, i.e. those with the most severe
diagnoses will be more prone to demanding SIT and those
patients with a low subjective perceived HRQL as measured
by a large difference in the visual analogue scale (VAS) scores
will be more likely to use a SIT treatment.
The aim of the present study is to investigate ‘differences’
between allergic rhinitis patients receiving SIT and allergic
rhinitis patients not receiving SIT. The focus will be to inves-
tigate whether socio-economic factors have any explanation,
when controlling for disease severity (both subjectively and
objectively). We believe more knowledge of the relative
importance of these factors may be of great importance
when developing strategies for improving the treatment of
allergic patients.
Methods
The allergen SIT group
For this case–control study, we recruited patients from 13
clinics specialized in specific allergy management. These
clinics were positioned all over the country of Denmark,
although the greatest proportion was from the metropolitan
areas and especially the region of Copenhagen with
172 patients (68%). Patients recruited for the control group
were all from the region of Copenhagen (see ‘The control
group’ section). The patients were consecutively invited to
participate as they were referred to SIT from their GP. The
patients were referred to the specialist clinics for treatment of
grass pollen and/or house dust mite allergy, during September
2005 to December 2006. Data were collected immediately
before SIT was initiated. The patients had to be at least 16
years of age to be included in the SIT group. Data were
collected by using specifically designed questionnaires for the
doctors and for the patients, respectively. A total of 254 par-
ticipants completed the questionnaire. Of these, 210 (82.7%)
had detectable serum-specific positive blood test for specific
Immunoglobulin E (IgE) to grass pollen and/or house dust
mites (IgE  0.35 k U/l) and were to start SIT. The specialist
doctors provided information about the patients’ general
health, disease duration and data on lung function as well as
specificity of allergy and immunotherapy treatment.
Furthermore, the doctors classified hay fever severity
according to the allergic Rhinitis and its impact on asthma
(ARIA) as intermittent or persistent.20,21 Doctors also
classified an eventual asthma according to the Global
Initiative for Asthma (GINA guideline).22,23
The control group
A group of persons reporting allergic rhinitis symptoms and
IgE sensitized to grass and/or house dust mites were estab-
lished from a general population study, the Health2006
Study. The Health2006 study took place between June 2006
and June 2008 and included 3471 persons aged 18–69 years
randomly selected from the general population in the region of
Copenhagen. Blood samples from all participants were
analysed for specific IgE against the four most clinically
important allergens in Denmark, i.e. birch, grass, cat and
house dust mite. Persons, who had received any forms of im-
munotherapy, were not included in the study. Persons, who
reported hay fever/asthma symptoms in the questionnaire and
who had a positive test for specific IgE against grass pollen
and/or house dust mite were selected for this study. These
persons completed the same questionnaire as the patient’s
questionnaire used in the SIT group. In addition, the partici-
pants in the Health2006 group classified their hay fever severity
according to the ARIA guidelines and their asthma (if relevant)
according to the GINA guidelines, thereby making it possible
to compare the socio-economic burden of ARD and HRQL
across the two groups.
Between June 2006 and September 2007, a total of 452
consecutive participants in the Health2006 who reported
symptoms of allergic rhinitis were asked to complete the ques-
tionnaire (see below). A total of 317 (70.1%) participants
completed the questionnaire. Of these, 156 had detectable
serum specific IgE to grass pollen and/or house dust mites.
Patients’ questionnaires
The patient questionnaire included a EQ-5D VAS
instrument24,25 and socio-economic questions. The
evaluation period was the 12 months before the day the
patients were filling in the questionnaires. The EQ-5D VAS
is a generic instrument, which allow researchers to compare
outcomes across a range of different diseases and in different
domains.26 The VAS instrument offers a simple method for
measurement of self-rated current health status. The VAS used
is a vertical 20 cm ‘thermometer’, it has endpoints of 100 (best
imaginable health state) at the top and 0 (worst imaginable
health state) at the bottom. The respondent rated his/her
health state on the VAS by drawing a line from the top box
marked ‘your health state on a typical day with no allergy
symptoms’ to the appropriate point on the VAS, and from
the base box ‘your health state on a typical day with allergy
symptoms’ on the VAS, thereby making it possible to calculate
the difference in the two VAS scores (referred to as delta-VAS).
Asking participants to report their HRQL in both settings
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enables estimation of the potential impact of allergy interven-
tions in a later stage, and it enables the calculation of a possible
impact of allergen exposure.
Information about the participant’s personal income and
household income for the year 2006 was collected from
Statistics Denmark for both the SIT and the Health2006
groups.
Analysis
Statistical analyses were performed using STATA 9.2
(StataCorp LP, College Stadion, TX, USA) and SPSS (SPSS
Inc. Chicago, IL, USA) for windows 15.0. Continuous
variables were described as mean 1 SD and categorical
variables were described as frequencies. Student’s t-test and
chi-squared test were used to test differences between the
SIT and control group for continuous and categorical
variables, respectively. P values of less than 0.05 were
considered statistically significant.
To further investigate differences between the SIT group and
the Health2006 group, we performed logistic regression
analyses with a dichotomous variable indicating whether the
individual belonged to the SIT group (=1) or control group
(=0) as dependent variable, and the following independent
variables, respectively: gender, age, severity of allergy and
asthma diagnosis, highest-attained education, delta VAS
score as well as household income from the year 2006.27,28
We controlled for possible interaction between severity of
diagnoses and other personal characteristics, by running a
similar regression analysis including only those respondents
with a severe allergy diagnosis or an asthma diagnosis.
Furthermore, since age may correlate with income and
education, we ran a regression which included respondents
under or equal to the age of 45 years and analysed the
impact of the remaining variables on SIT demand.
Subjective need as measured by respondents’ perceived
decrease in HRQL (delta-VAS score) may depend on life ex-
pectations. Such expectations may be a function of age and
education. In order to test whether a possible impact of these
person characteristics on SIT may be explained by different
subjective perceptions of HRQL, we tested whether HRQL
differed statistically significantly across these groups when
holding severity of allergy diagnosis constant.
Results
Table 1 shows that participants in the SIT group were signifi-
cantly younger, were more likely to have an upper secondary
school education and they were more likely to have a short or
medium high education or a university degree than partici-
pants from the Health2006 group. Participants in the SIT
group also had a significantly lower personal income and
household income than participants from the Health2006
group.
As shown in table 2, the predominant part of the partici-
pants in the SIT group was classified as having persistent rhino
conjunctivitis (RC) (96.2%) when compared with the
Health2006 group (55.8%). Approximately half of the partici-
pants in the SIT group were diagnosed with asthma, as
compared with 18.6% in the Health2006 group. Interestingly,
participants from the SIT group reported fewer years with
allergy/asthma symptoms when compared with the
Health2006 group, but participants from the SIT group had
been bothered significantly more months during the last year
compared with participants from the Health2006 group.
Participants from the SIT group had been in contact with
emergency rooms significantly more often than participants
from the Health2006 group.
Table 2 also shows that participants in the SIT group had
lower HRQL than participants in the Health2006 group on
days with allergy symptoms measured on the VAS
instrument (P< 0.001), whereas it was higher on days with
no allergy symptoms. The mean delta-VAS score (i.e. the
perceived decrease in HRQL) was significantly higher in the
SIT group as compared with the Health2006 group.
Table 3 shows the logistic regression analysis of participants
selecting a SIT treatment with respect to gender, age, RC
severity, an asthma diagnosis, highest attained education,
household income and delta-VAS. Patients in the Health2006
group were more likely to be younger of age, have persistent
RC and concomitant asthma, when compared with the
patients in the SIT group. In a preliminary analysis, we
Table 1 Demographic and socio-economic characteristics of the patients
Health2006 group
n=156
SIT group
n=210
P-value
Gendera
Male 77 (49.4) 111 (52.9) 0.508
Age in yearsb
Mean (SD) 44.6 (12.0) 33.4 (10.9) <0.001
Range in year 19.2–68.3 16.1–66.3
School educationa
Basic school (7–10 years) 74 (47.4) 52 (24.8) <0.001
Upper secondary school (12 years) 72 (46.2) 143 (68.1) <0.001
Other school education (9 years + additional school education) 10 (6.4) 15 (7.1) 0.784
Highest attained educationa
Vocational education and training 32 (20.5) 31 (14.8) <0.149
Short or medium high education 84 (53.9) 68 (32,4) <0.001
University degree 16 (10.3) 68 (32.4) <0.001
Other education or unknown 9 (5.8) 13 (6.2) 0.867
No education 15 (9.6) 30 (14.3) 0.178
Smoking statusa
Current smoker 28 (18.0) 27 (12.9) 0.178
Former smoker 39 (25.0) 44 (21.0) 0.360
Never smoker 89 (57.1) 139 (66.2) 0.074
Mean (SD) personal income in DKK in the year 2006b 371 389 (242 818) 288 225 (245 685) 0.001
Mean (SD) household income in DKK in the year 2006b 628 789 (340 907) 546 167 (349 230.5) 0.025
Values are number of participants (%), if not stated otherwise
a: Pearson Chi-square test
b: Student’s t-test were used to test differences between the allergen specific immunotherapy group and the control group for
continuous variables and categorical variables, respectively
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controlled for smoking status and interaction between
education and respiratory symptoms. Patients in the SIT
group were more likely to have a university degree, and a
greater delta-VAS score, indicating that their self-perceived
need for SIT was significantly higher. The regression analysis
showed that household income did not influence the patient
choice of SIT treatment when taking into account differences
in age between the SIT and Health2006 groups.
In order to control for any correlation that may occur
between the objective need variables and other explanatory
variables, a regression analysis was performed, where the
analysis only included patients with persistent RC and/or
patients with an asthma diagnosis (‘objective need’ for SIT
was thus held constant); see table 4.
When controlling for severity of disease according to the
diagnosis, age, high level of education as well as subjective
perception of HRQL remain statistically significant explana-
tory factors. Having a university degree is, however,
associated with lower odds ratios of 28.61. When, in
addition, controlling for age by looking at only the younger
age group (under or equal to the age of 45 years) the odds ratio
for education is reduced to 7.23 (suggesting some correlation
between age and level of education). Controlling for age does
not change the result that income has no effect on the con-
sumption of SIT. Also a regression analysis was performed
which included income but not education as a potential ex-
planatory variable (both in tables 3 and 4). In both cases,
income remained statistically insignificant.
Focusing only on patients diagnosed with persistent RC or
asthma, it was found that respondents under or equal to the
age of 45 (n= 231) had a mean delta-VAS score of 35.9, while
older respondents (n= 69) had a mean delta-VAS score of 25.7.
These scores were statistically significantly different
(P< 0.001). When performing the same analysis for people
with university degrees versus all others, there was a
tendency to a lower perceived HRQL amongst those with no
university degree, but the difference was not statistically sig-
nificant (P=0.165).
Concerning the other independent variables in the model
(table 3) we controlled for interactions, but did not find any
(e.g. education level, income and age).
Discussion
In this study, it was found that measures of severity of RC on
days with hay fever symptoms, concomitant asthma, HRQL
and socio-economic status (educational level) were significant-
ly associated with receiving a SIT treatment. These results
indicate that participants from the SIT group were more
severely affected by their allergy/asthma disease as compared
with the Health2006 group. In addition we found that
increasing age was associated with a lower probability of
receiving a SIT treatment, which supports our hypothesis
that older people, who have fewer years in which they can
enjoy the positive health outcomes associated with SIT, are
more willing to cope with their allergy symptoms as
compared with younger people. The study also showed that
not only objective need for SIT but also self-perceived HRQL
(delta-VAS score) impacted on the demand for SIT. Amongst
the younger group of patients (45 years) with a severe
diagnosis, the detriment HRQL due to allergy/asthma was
perceived as being lower; suggesting that an additional
motivation for younger individuals to demand SIT is that
their HRQL are affected more severely by allergy.
Table 2 RC (hay fever), asthma and HRQL classification of the participants
Health2006 group
n=156
SIT group
n=210
P-value
Positive test for specific IgE to grass pollen 138 (88.5) 184 (87.6) 0.806
Positive test for specific IgE to House dust mite 60 (38.5) 65 (31.0) 0.134
RC classification
No RC classification (intermittent or persistent) 9 (5.8) 5 (2.4) 0.095
Intermittent RC 60 (38.5) 3 (1.4) <0.001
Persistent RC 87 (55.8) 202 (96.2) <0.001
Asthma diagnosis 29 (18.6) 103 (49.1) <0.001
Self reported duration of allergy/asthma in years
Mean (SD) 23.2 (13.8) 17.3 (11.4) <0.001
Range in year 0–57 0–54
Number of months uncomfortable because of allergy/asthma symptoms in the last year
Mean (SD) 3.3 (3.3) 6.5 (4.0) <0.001
Range in month 0–12 0–12
Emergency room visit during the last year because of allergy/asthma 6 (3.9) 30 (14.3) 0.001
HRQL
VAS on days with no allergy symptoms, mean (SD) 0.87 (0.11) 0.91 (0.09) 0.001
VAS on days with allergy symptoms, mean (SD) 0.70 (0.18) 0.50 (0.20) <0.001
Delta-VAS, mean (SD) 0.17 (0.15) 0.41 (0.20) <0.001
Values are number of patients (%), if not stated otherwise
Table 3 Logistic regression analysis with SITa (=1) or not (=0)
as the dependent variable (n=351)
SIT treatment (number of observations) Odds
ratio
95% CI
Gender (366)
Female (178) 1.00 Reference
Male (188) 1.98 0.92–4.26
Age (366) 0.92 0.89–0.95
RC severity (366)
No RC or intermittent RC diagnosis (77) 1.00 Reference
Persistent RC (289) 32.92 9.16–118.35
Asthma (366)
No asthma diagnosis (234) 1.00
Asthma diagnosis (132) 4.19 1.86–9.44
Highest attained education (366)
No education (45) 1.00 Reference
Vocational education and training (63) 2.25 0.56–8.99
Short or medium high education (152) 3.46 0.99–12.09
University degree (84) 51.79 10.38–258.33
Other education or unknown (22) 6.50 0.87–48.55
Household income in 2006 in DKK 100000 (363) 1.00 0.89–1.11
Delta-VAS score (354) 1.11 1.08–1.15
CI: confidence interval
a: Allergen-specific subcutaneous injection immunotherapy
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Our results suggest that income does not impact on the use
of SIT, which implies that out-of-pocket payment does not
constitute a significant barrier. Patients with a high level of
education receive SIT to a greater extent than those with
lower levels of education, which may be an indication of
other types of barriers to treatment access. For example,
educated persons tend to live in regions with a higher
frequency of specialists and/or GPs with an interest in
immunology. Since those living in metropolitan areas are
higher educated and there is a higher availability of
providers of SIT in these regions, these factors may in com-
bination provide an explanation for the great variations in the
vaccination rates and turnover between the five administrative
regions in Denmark. Alternatively, there may be an informa-
tion availability bias that favours the more highly educated.
The study may also be biased by the selection process since
the patients in the SIT group have first been persuaded to SIT
by their GP (assuming uninformed patients) or have
persuaded their GP (assuming informed patients) to
prescribe SIT. Second, patients in the SIT group have
adhered to the prescription by the GP and have attended the
specialist clinic. Third, they have agreed to respond to the
questionnaire.
We cannot exclude the possibility that the observed differ-
ences in socio-economic variables may be an artefact of the
samples selected. This is, however, highly unlikely since the
control cohort and the main part of the intervention cohort
(68%) are very similar in geography. Although there might be
other known and unknown factors, which contribute to the
difference of both groups, we do not have a clear explanation
for this. This topic may be interesting to study in future
research where a qualitative approach could possibly be the
most appropriate choice.
The study participants in the SIT group were interviewed
just prior to the start of SIT treatment. To the extent that
participants have an inclination to justify their choice of SIT
by exaggerating their symptoms on a day with allergy
symptoms, this may bias the presented results.
The study required that the respondents recalled a typical
day with allergic symptoms during the past 12 months; hence
our results may be affected by recall bias.
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Key points
 The consumption of allergy-vaccination is complex,
since the characteristics of patients receiving SIT are
dependent not only on the patients’ objective need, but
equally important, on the patients’ own perceived
HRQL.
 Household income does not impact on which patients
receive SIT.
 Patients with the highest levels of education, especially
those with a university degree, are significantly more
likely to seek SIT as compared with patients having
other educational levels, suggesting the existence of
social inequality in allergy treatment in Denmark.
 Our results represent valuable information which may
guide future attempts to develop strategies for public
health policy and practice to decrease under-treatment
of ARD.
 Some barriers to treatment may be reduced by future
introduction of sublingual and tablet-based
immunotherapy which can be administered at home
and requires fewer visits to the doctor.
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